With the news cycle currently dominated by reports of various countries legalizing recreational marijuana, it’s easy to forget that that road to legalization has been in the works for decades.
Much of the reason countries like Canada have legalized cannabis today stems from the activism, work and longstanding diligence of medical cannabis advocates — people like Steph Sherer, who has spent 20 years speaking about the positive effects of medicinal cannabis.
At the Collision Conference in Toronto, the Investing News Network sat down with Sherer, who is president of Americans for Safe Access (ASA), president and co-founder of the International Cannabis and Cannabinoids Institute (ICCI) and co-founder of Dioscorides Global Holdings (DGH).
She discussed the long path to medical cannabis legalization in America, how the prevalence of recreational marijuana has affected her advocacy work and her work at DGH, a private equity firm.
Correcting medical cannabis misconceptions
In 2002, Sherer founded the ASA, the largest national organization of patients, medical professionals, scientists and citizens promoting safe and legal access to cannabis for therapeutic use and research.
Her work at ASA led to her co-founding the ICCI in 2015. The Czech Republic-based center ensures that medical cannabis products are effective, safe and consistent.
After spending two decades advocating for medical cannabis, Sherer has seen and heard a lot, but she noted that getting the general public to view therapeutic marijuana as a medical need and not a party drug has been one of the main challenges.
“The biggest misconception about medical cannabis is that the use makes you just feel better — not necessarily makes you better,” explained Sherer. “I think a lot of people think about medical cannabis as an option for a last resort. (If) nothing else is working, maybe doctors will turn to medical cannabis. I think often people look at medical cannabis users as people just feeling better, but not getting better.”
For Sherer, who uses medical cannabis to treat multifocal dystonia and torticollis, breaking down the false information, misconceptions and stigma remains paramount.
“What I’m seeing in my own personal use of medical cannabis and also as a patient advocate, we know that people aren’t just feeling better, but they’re getting better,” she said.
Separating medical and recreational cannabis
When it comes to recreational marijuana, the longtime advocate has mixed feelings. While working to create universal access, she has seen valuable research and development dollars that could advance the case for medical marijuana invested in other niche areas that she views as less important.
“On one side, it creates an opportunity for access for a patient who couldn’t convince their doctor to write a recommendation to help them with access,” said Sherer.
But she thinks a clear definition between fun weekend use and the management of chronic conditions needs to be implemented.
“What patients want and need from the plant is very different than somebody that may just want to enjoy a concert on a weekend. I’ve seen the investment in research and development move away from moving medical cannabis into something that looks more familiar to doctors and patients as a medicine (toward) trying to get rid of the flavor of cannabis in a soft drink or how to get as high as possible.”
Sherer even jokingly noted that renaming cannabis may help to reduce some of the stigma, pointing to the commercial success of cannabidiol (CBD) products.
“When I started ASA in 2002, the first thing I said is, ‘Please come up with a new name for cannabis.’ I think in that way it’s made it easier for maybe soccer moms to try CBD, and maybe that opens their mind to thinking about other cannabis products,” she said.
“My fear is that, because it’s not a very regulated market, there’s a lot of fraud or products that actually have no CBD in them. There’s a lot of product safety issues in that field that may have the opposite effect. Maybe someone tries one of these products, it says it’s CBD (and) they have an adverse reaction to the contaminants, or maybe they don’t have any reaction because there’s no CBD in it. In their minds, they just close their minds to actually trying other medical cannabis products in the future.”
Research and development still paramount
That is where research and medical studies come into play. Much of the work that the ICCI is doing internationally is focused on implementing standardization, regulation and oversight.
Meanwhile, DGC, a private equity firm that Sherer formed with business partner Ben Bronfman, invests strategically in the medical cannabis sector in order to advance the much-needed research that will help the sector gain widespread acceptance and legalization.
“We’re looking for investments that move medical cannabis towards being a medicine. That means investing in medical cannabis providers,” she said.
One of the companies DGH has invested in is Bedrocan International.
“It’s one of the oldest medical cannabis companies that has been providing standardized products to the Dutch government since 2003. They’re in pharmacies in 19 countries, and we wanted to make sure that their goals, their ethics, their mission have the potential for a global audience and are able to reach patients globally,” said Sherer.
The private equity company was also crucial in the establishment of the ICCI, an international medical cannabis advocacy and research organization.
“Cannabis is a very, very researched plant, but the research hasn’t happened in a way that builds on itself,” said Sherer. “A lot of research that’s happening, it can’t be replicated. We’re investing in the technologies that allow research to happen and allow the global companies that are out there to have a commitment to providing medical cannabis to patients. We’ve created platforms that will save these companies time and money to move into clinical trials right away and to really carry out the intended mission of medical cannabis.”
Due to its relatively new legal status in a handful of countries around the world, many people believe that the work for medical cannabis advocates is over, when in fact it has become more important.
“Until cannabis is in a pathway that looks more like medicine covered by insurance, our work isn’t done.”
Don’t forget to follow us @INN_Resource for real-time updates!
Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.